Sanjivani Paranteral to Discuss Q4 FY26 Results on May 15 Call

Conference Call Announcement

Sanjivani Paranteral Limited has announced an analyst and investor conference call scheduled for Friday, May 15, 2026, at 11:00 AM IST. The company's Chairman and Chief Financial Officer are expected to participate.

Focus on Q4 FY26 Performance and Outlook

The primary agenda for the call is to review Sanjivani Paranteral's financial performance for the fourth quarter of fiscal year 2026 (Q4 FY26). This session offers a direct opportunity for investors and analysts to engage with the company's leadership, gain clarity on its results, and understand its strategic direction and future prospects.

Company Background and Recent Financials

Sanjivani Paranteral is an Indian pharmaceutical firm specializing in the manufacture of sterile injectables and ophthalmic preparations. The company has faced financial challenges, posting net losses in recent fiscal years such as FY23 and FY24. Its latest reported results for Q3 FY26 showed a standalone net loss of ₹7.75 crore on revenues of ₹13.19 crore.

Key Financial Data Highlights

Key financial figures reported for Q3 FY26 include standalone revenue of ₹13.19 crore and a standalone net loss of ₹7.75 crore. For the full fiscal year 2023 (FY23), the company recorded a standalone net loss of ₹66.50 crore.

Caution on Forward-Looking Statements

Sanjivani Paranteral has cautioned that discussions may include forward-looking statements. These statements are subject to inherent risks and uncertainties, meaning actual financial results and business outcomes could differ significantly due to potential changes in the economic landscape or other unforeseen factors.

Competitive Landscape

In the competitive Indian market for sterile injectables, Sanjivani Paranteral faces key players like Gland Pharma Limited and Strides Pharma Science Limited, who operate within similar segments.

Investor Watchlist

Investors and shareholders are encouraged to participate in the call for direct updates on the company's financial health and strategy. Management's commentary will be critical for insights into plans for FY27 and beyond, as well as any revised financial outlook or guidance.